ArticleInternational journal of cancer2025
The prognostic potential of RNA in stage II colon cancer: Insights from a screened multicenter population-based cohort study.
Article in International journal of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The impact of age on survival in stage II colon cancer: a SEER database analysis stratified by chemotherapy status.Translational cancer research · 2026Article
- Transcriptional profiling of the tumor microenvironment of recurrent and non-recurrent stage II colon cancer.Scientific reports · 2026Article
- The prognostic potential of RNA in stage II colon cancer: Insights from a screened multicenter population-based cohort study.International journal of cancer · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The management of stage II colon cancer poses an important clinical challenge due to difficulties in identifying patients at risk of recurrence. RNA expression profiles in solid tissues have demonstrated a strong potential as prognostic markers. The objective of this study was to develop an RNA-based risk score to risk-stratify patients with stage II colon cancer using a large, well-characterized, and screened patient cohort. This multicenter cohort study encompasses tissue samples collected from all surgically resected stage II colon cancer patients in the Region of Southern Denmark from 2014 to 2016 (n = 739). Gene expression analysis was performed on 122 RNAs, previously described as holding prognostic potential in colorectal cancer, using NanoString nCounter analyses. The resulting RNA expression profiles were used to develop a score predicting the risk of recurrence. The primary endpoint for the study was time to recurrence (TTR), with overall survival (OS) as a secondary endpoint. A dichotomized score, derived from the combined expression of four RNAs (ZNF697, SNORA2B, CTSC and OXLD1), effectively predicted TTR in stage II colon cancer patients. The score revealed a hazard ratio (HR) of 6.84 in univariate analysis (p < 0.001) and a HR of 5.00 in multivariate analysis (p < 0.001), surpassing the prognostic performance of known clinical risk factors. Additionally, the score was significantly associated with OS in Kaplan-Meier analysis (p = 0.024). In conclusion, this four-gene expression score demonstrates a strong association with TTR in stage II colon cancer patients, providing valuable prognostic insights that extend beyond conventional clinical risk markers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.